Get notified when PLSE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate Dilution of $35.58 Per Share (new) — New investors would see most of their purchase price not backed by tangible assets, with as-adjusted net tangible book value per share of only about $2.32.
Pulse Biosciences launches at-the-market offering to sell up to $75M of common stock at $37.90 per share
Filed August 6, 2026 · ~1 min read
Key Changes
-
high
Pulse Biosciences may sell up to $75 million of common stock through Mizuho as agent, with no minimum offering amount.
The Offering verify on EDGAR → -
high
The offering is at-the-market, so shares will be sold at prevailing market prices over time, and investors may pay different prices.
Risk Factors verify on EDGAR → -
high
Proceeds are earmarked for general corporate purposes, including clinical studies and regulatory submissions for the nPulse Cardiac Catheter.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAR 10-Q) is open in full — no account needed.
Partner
Trade PLSE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify